BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30790732)

  • 21. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
    Suren D; Isiksacan Ozen O
    J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
    Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.
    Wong E; Nahar N; Hau E; Varikatt W; Gebski V; Ng T; Jayamohan J; Sundaresan P
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):5-9. PubMed ID: 29336530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
    Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
    Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
    Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
    Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.
    Ahmadipour Y; Jabbarli R; Gembruch O; Pierscianek D; Darkwah Oppong M; Dammann P; Wrede K; Özkan N; Müller O; Sure U; El Hindy N
    World Neurosurg; 2019 Feb; 122():e461-e466. PubMed ID: 30347300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.
    Henker C; Kriesen T; Fürst K; Goody D; Glass Ä; Pützer BM; Piek J
    J Neurooncol; 2016 Feb; 126(3):585-92. PubMed ID: 26603163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[
    Harat M; Małkowski B; Roszkowski K
    Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.
    Reavey-Cantwell JF; Haroun RI; Zahurak M; Clatterbuck RE; Parker RJ; Mehta R; Fruehauf JP; Brem H
    J Neurooncol; 2001 Dec; 55(3):195-204. PubMed ID: 11859975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma.
    Alexiou GA; Zikou A; Tsiouris S; Goussia A; Kosta P; Papadopoulos A; Voulgaris S; Kyritsis AP; Fotopoulos AD; Argyropoulou MI
    Clin Neurol Neurosurg; 2014 Jan; 116():41-5. PubMed ID: 24309151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Imaging Biomarkers in Glioblastoma: Development and Independent Validation on the Basis of Multiregion and Quantitative Analysis of MR Images.
    Cui Y; Tha KK; Terasaka S; Yamaguchi S; Wang J; Kudo K; Xing L; Shirato H; Li R
    Radiology; 2016 Feb; 278(2):546-53. PubMed ID: 26348233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
    Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
    Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma.
    Chen L; Lin ZX; Lin GS; Zhou CF; Chen YP; Wang XF; Zheng ZQ
    Hum Pathol; 2015 Jan; 46(1):120-8. PubMed ID: 25455996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.